News

Urgent Action Required for SelectQuote Investors Ahead of Deadline

Urgent Action Required for SelectQuote Investors Ahead of Deadline

Important Deadline for SelectQuote Investors

Attention SelectQuote investors! A significant deadline is approaching that demands immediate attention. If you are among those who purchased shares of SelectQuote Inc. (NYSE: SLQT) between September 9, 2020, and May 1, 2025, you may have legal rights that could support your investment recovery.

Contact Information for Legal Guidance

Bragar Eagel & Squire, P.C., a well-established law firm, is ready to assist shareholders who suffered losses related to their investments in SelectQuote. If this resonates with your situation, connect with Brandon Walker or Marion Passmore at (212) 355-4648 to discuss your options.

What’s Happening in the Case

A class action lawsuit has been initiated against SelectQuote, highlightng events that could impact its valuation significantly. The lawsuit encompasses all individuals and entities who obtained SelectQuote securities during the designated class period. As the situation unfolds, investors have until October 10 to seek a lead plaintiff position within the lawsuit.

Allegations Raised Against SelectQuote

The allegations against SelectQuote are severe, involving a complaint filed by the U.S. Department of Justice. It has been claimed that the company engaged in questionable practices between 2016 and 2021 concerning its dealings with Medicare beneficiaries. This purportedly included steering beneficiaries towards certain health plans for company gain, all whilst presenting itself as providing unbiased assistance.

Impact on Stock Performance

This news has had a noticeable effect on SelectQuote's stock price, which saw a decline of 19.2% following the allegations. When faced with adverse public perception, investors may find their stock losing value rapidly, emphasizing the importance of understanding one’s rights during such turbulent times.

Understanding Your Rights

It's crucial for shareholders to be proactive, especially amidst such critical news. Shareholders who have incurred losses or who possess information that could be relevant to these claims should not hesitate to reach out. Your participation can be pivotal for the class action and could pave the way for potential compensation.

About Bragar Eagel & Squire, P.C.

Bragar Eagel & Squire is recognized nationally for its commitment to securing the rights of shareholders and has an extensive history of litigation in both state and federal courts. Investors are encouraged to explore their legal options through the firm’s professional guidance.

Frequently Asked Questions

What is the deadline for SelectQuote investors to act?

The deadline for investors to apply as lead plaintiffs in the lawsuit is October 10, 2025.

How can I participate in the class action lawsuit?

Investors can reach out to the named law firm, Bragar Eagel & Squire, P.C. for assistance in joining the lawsuit.

What damages are being sought in the lawsuit?

The lawsuit aims to address financial losses incurred by investors due to SelectQuote's alleged misconduct.

Who should I contact for more information?

Brandon Walker and Marion Passmore from Bragar Eagel & Squire, P.C. are available at (212) 355-4648 for more details.

Is there a cost to participate in the lawsuit?

There is no cost or obligation for investors who choose to consult with the law firm regarding their participation in the lawsuit.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Historic Records Set at 2026 CNO Monumental Marathon

Updated Category News Views 421

Race to Remember: Monumental Breakthroughs In the chilly November air of Indianapolis, the 2026 CNO Financial Indianapolis Monumental Marathon wasn't just another tick on the calendar—this was a banner day for running. With record-breaking performances across every distance, we saw what happens when a community of athletes, sponsors, and volunteers hits a perfect...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 253

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
J&J's New Study: Sjögren’s Solution Insight Sparks Debate

Updated Category News Views 281

Patient-Centric Take on Sjögren's Disease Johnson & Johnson has dropped fresh Phase 2 results on nipocalimab, reminding everyone they're at the helm of reshaping treatments for Sjögren's disease (SjD). A condition leaving about four million folks craving better days, in multiple ways, shines a light on what's gripping patients the hardest. It's hard not to sit up and...

Continue Reading
Johnson & Johnson Unveils Promising PsA Treatment Data

Updated Category News Views 282

A Game-Changer in Psoriatic Arthritis Treatment? Johnson & Johnson just tossed a headline-grabbing bone into the world of psoriatic arthritis with their new ICOTYDE results. For anyone tangled in the chronic web of psoriatic arthritis, hearing about a potential new treatment like ICOTYDE comes with cautious hope. Between stiff joints and rashy skin, sufferers are often...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 34

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
NatGold Pulling NATG From MEXC Amid Security Concerns

Updated Category News Views 536

NatGold Digital's sudden decision to yank its NATG token off MEXC Global reeks of regulatory urgency. With the U.S. Treasury clamping down on fund transfers wrapping up MEXC in their action against Russian laundering, NatGold didn't wait for the ink to dry on that order. They’re off the exchange posthaste. A bit of foresight or sheer necessity? Well, it's got the market...

Continue Reading
Invasive Procedures Don't Extend Life in Stable Heart Disease

Updated Category News Views 462

Challenging Longstanding Beliefs Today’s news from the heart research front might set a few cardiology heads spinning. We’ve got big-time findings out of the ISCHEMIA-EXTEND study, throwing more weight on the evidence pile that early invasive heart procedures for patients with stable coronary artery disease don’t actually extend your life. Managing care with a blend...

Continue Reading
Evaluating GLP-1 Telehealth? Key Questions to Consider

Updated Category News Views 547

Navigating the Landscape of GLP-1 Telehealth Providers In the sprawling jungle of telehealth options for GLP-1 care, it's easy to feel like you're drowning in sameness. Picture this: you land on a sleek page promising the moon and stars, but who knows what's behind the curtain? That's where seasoned advice comes in, like a compass in this murky digital forest. Meant, a...

Continue Reading
2027 Toy of the Year Finalists Energize Play Market

Updated Category News Views 308

A Kaleidoscope of Innovation in Toys There's a familiar buzz in the air, folks. The 2027 Toy of the Year Awards finalists have been unveiled, and they're bringing a fresh wave of creativity to children's playrooms. These aren't just toys; they're miniature innovators ready to light up the market this holiday season. The reveal happened at the Chicago Toy & Game Fair and...

Continue Reading
Boston STEM Expo Sparks Young Minds in Engineering

Updated Category News Views 243

If you really want to light up a kid's imagination, throw them into a room full of science experiments and let 'em have at it. That's exactly what happened at the recent Society of Women Engineers' Innovation Expo in Boston's Seaport District. The place was buzzing, and not just because of all the engineering gadgets on display—it was the energy of young minds...

Continue Reading

Top 5 Most Recently Viewed Articles

Silexion Therapeutics to Showcase Innovations at Upcoming Conference

Updated Category News Views 127

Silexion Therapeutics and Its Future in Oncology Silexion Therapeutics Corp. is at the forefront of the biotechnology sector, focusing its efforts on innovative treatments specifically designed for oncology. This clinical-stage company is dedicated to transforming the landscape for patients with hard-to-treat cancers, primarily those with the mutated KRAS oncogene, known...

Continue Reading
UBS Predicts Slowdown in Nvidia-Led Tech Rally - Key Insights

Updated Category News Views 172

UBS Foresees Changes in Tech Rally Dynamics Analysts at UBS suggest that the excitement surrounding the recent tech rally, driven by Nvidia, is beginning to wane. They predict a shift towards a more volatile market environment, influenced by ongoing economic challenges and increasing regulatory scrutiny in the semiconductor sector. Analysts' Perspectives on Future Stock...

Continue Reading
OS Therapies (OSTX) Unveils Encouraging Survivorship Data

Updated Category News Views 222

OS Therapies Inc. Reports Promising Results in Bone Cancer Therapy OS Therapies Inc. (NYSE: OSTX), a company focused on developing innovative cancer treatments, recently reported compelling findings from its Phase 2b clinical trial on OST-HER2, an off-the-shelf immunotherapy designed for addressing osteosarcoma, a challenging form of bone cancer. Significant Survival Data...

Continue Reading
Jeito Capital Boosts Aviceda Therapeutics with $207.5M Funding

Updated Category News Views 239

Jeito Capital's Strategic Investment in Aviceda Therapeutics Jeito Capital has recently announced a significant investment in Aviceda Therapeutics, securing a substantial participation in an upsized $207.5 million Series C financing round aimed at advancing the company's lead program, AVD-104. This funding is specifically intended to support pivotal trials for AVD-104,...

Continue Reading
Apple's Innovative M4 Mac Mini Sets New Standards in Tech

Updated Category News Views 293

Apple Launches the Game-Changing Mac Mini Apple Inc (NASDAQ: AAPL) has once again captivated technology enthusiasts and consumers alike with its latest innovation — the redesigned Mac mini equipped with groundbreaking M4 and M4 Pro chips. This launch not only showcases Apple's commitment to performance but also its pioneering approach to sustainability, marking the Mac...

Continue Reading